Cormorant Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Cormorant Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,000,000	Closed	-$4.05M	–	45
2025 Q1	$4.05M	Buy	+3,000,000	New	+$18.2M	0.3%	41
2023 Q2	–	Sell	-1,444,000	Closed	-$38.4M	–	72
2023 Q1	$38.4M	Buy	1,444,000 +661,212	+84%	+$18.8M	2.53%	12
2022 Q4	$15.1M	Hold	782,788	–	–	1.01%	32
2022 Q3	$16.4M	Buy	782,788 +300,375	+62%	+$5.75M	1.14%	31
2022 Q2	$3.86M	Hold	482,413	–	–	0.29%	55
2022 Q1	$3.38M	Hold	482,413	–	–	0.26%	55
2021 Q4	$6.51M	Hold	482,413	–	–	0.39%	51
2021 Q3	$8.14M	Hold	482,413	–	–	0.33%	58
2021 Q2	$14M	Sell	482,413 -128,996	-21%	-$4.02M	0.48%	49
2021 Q1	$24M	Hold	611,409	–	–	0.54%	39
2020 Q4	$13.9M	Hold	611,409	–	–	0.33%	59
2020 Q3	$13.6M	Hold	611,409	–	–	0.52%	47
2020 Q2	$18.8M	Buy	+611,409	New	+$16.2M	0.72%	46

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Cormorant Asset Management's PLRX Position: Q2 2025 in Review

Cormorant Asset Management sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 3,000,000 shares — an estimated $4.05M sold.

Cormorant Asset Management first reported a position in PLRX in Q2 2020 and held it in 13 quarters. The position peaked at $38.4M in Q1 2023. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

Cormorant Asset Management reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
Cormorant Asset Management sold 3,000,000 Pliant Therapeutics shares in Q2 2025, an estimated $4.05M.
Cormorant Asset Management first reported a position in Pliant Therapeutics in Q2 2020 and held it in 13 quarters.
Cormorant Asset Management's Pliant Therapeutics position peaked at $38.4M in Q1 2023.
114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Cormorant Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.